Physician profile
Howard A Smith
NPI 1194799411
$1,079.14
in general payments reported to CMS, 2019-2025
17 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.15 · 2022: $69.84 · 2023: $236 · 2024: $142 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $192.08 | 2023-2025 | Bexsero, Rotarix, Pediarix |
| Merck Sharp & Dohme LLC | $167.24 | 2023-2025 | Pifeltro, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $147.51 | 2021-2025 | |
| Abbvie INC. | $129.17 | 2022-2024 | |
| Gilead Sciences, INC. | $98.64 | 2025 | Yeztugo |
| Alkermes, INC. | $64.33 | 2025 | Aristada, Lybalvi |
| Organon LLC | $54.28 | 2022 | |
| Alk-Abello, INC | $32.41 | 2025 | Odactra, Ragwitek, Grastek |
| Viiv Healthcare Company | $29.20 | 2024 | Apretude |
| Phadia US INC. | $27.82 | 2024 | Immunocap |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.69 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $23.50 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $19.88 | 2023 | Hetlioz, Fanapt |
| Indivior INC. | $17.95 | 2023 | Perseris |
| Kowa Pharmaceuticals America, INC. | $17.93 | 2025 | Zoryve |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $17.59 | 2024 | Rexulti |
| Almatica Pharma LLC | $13.92 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.